SS-31 10mg 10vials
Original price was: $210.00.$170.00Current price is: $170.00.
SS-31 mitochondrial peptide with detailed comparison guide. Compare benefits for cardiovascular, neurological, and cellular energy research applications.
Free shipping on orders over $1500! 100% delivery
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
Description
SS-31 offers researchers a comprehensive mitochondrial support system suitable for diverse research applications. This versatile peptide provides opportunities for comparative studies across cardiovascular, neurological, and cellular energy research contexts.
What is SS-31?
SS-31 represents an advance in mitochondrial-targeted therapy, offering researchers multiple pathways to investigate cellular energy metabolism, oxidative stress protection, and therapeutic interventions across various health conditions.
| Research Application | Primary Benefits | Study Duration | Typical Dosage |
|---|---|---|---|
| Cardiovascular Studies | Heart function improvement | 8-12 weeks | 30-40mg daily |
| Neurological Research | Neuroprotection, brain energy | 6-16 weeks | 20-40mg daily |
| Aging Research | Cellular longevity, energy | 12+ weeks | 20-30mg daily |
| Performance Studies | Exercise capacity, recovery | 6-8 weeks | 30-40mg daily |
SS-31 Benefits and Effects
| Benefit Category | Mechanism | Research Evidence | Clinical Relevance |
|---|---|---|---|
| Mitochondrial Function | Cardiolipin stabilization | Extensive clinical trials | Energy metabolism disorders |
| Cardiovascular Health | Improved cardiac efficiency | Phase II trials | Heart failure research |
| Neuroprotection | Brain energy support | Preclinical studies | Neurodegenerative conditions |
| Anti-Aging | Oxidative stress reduction | Longevity studies | Cellular aging research |
SS-31 Side Effects and Safety
Comparative safety analysis across different research applications demonstrates consistent tolerability with minimal adverse effects.
| Safety Parameter | Short-term Use | Long-term Studies | High-Dose Research |
|---|---|---|---|
| Overall Tolerance | Excellent | Very Good | Good with monitoring |
| Side Effects | Minimal | Mild, manageable | Moderate, monitored |
| Monitoring Needs | Basic assessments | Regular evaluations | Comprehensive tracking |
| Safety Margins | Wide | Established | Well-defined |
Main SS-31 Use Cases
| Research Focus | Primary Applications | Expected Outcomes | Study Design |
|---|---|---|---|
| Cardiovascular | Heart failure, ischemia | Improved cardiac function | Randomized controlled trials |
| Neurological | Cognitive decline, neuroprotection | Enhanced brain function | Longitudinal studies |
| Metabolic | Energy disorders, aging | Cellular energy improvement | Biomarker studies |
| Performance | Athletic capacity, recovery | Enhanced physical function | Performance testing |
SS-31 Dosage Guidelines
| Research Type | Starting Dose | Optimal Range | Maximum Dose | Frequency |
|---|---|---|---|---|
| Basic Research | 20mg | 20-30mg | 40mg | Daily |
| Clinical Studies | 20mg | 30-40mg | 40mg | Daily |
| Performance Research | 30mg | 30-40mg | 40mg | Daily |
| Long-term Studies | 20mg | 20-30mg | 40mg | Daily |
SS-31 Cycle Guidelines
Flexible cycling approaches accommodate different research objectives while maintaining optimal safety and efficacy standards.
| Study Type | Cycle Length | Monitoring Frequency | Assessment Points |
|---|---|---|---|
| Acute Studies | 2-4 weeks | Weekly | Baseline, mid-point, end |
| Standard Research | 8-12 weeks | Bi-weekly | Every 4 weeks |
| Extended Studies | 16+ weeks | Weekly | Every 4-6 weeks |
| Comparative Studies | Variable | Protocol-specific | Study-dependent |
SS-31 Administration Guide
Standardized administration protocols ensure consistent results across different research applications and study types.
| Administration Aspect | Standard Protocol | Research Considerations |
|---|---|---|
| Preparation | Sterile reconstitution | Consistent technique across studies |
| Delivery Method | Subcutaneous injection | Site rotation for long-term studies |
| Timing | Daily, consistent time | Aligned with study objectives |
| Documentation | Detailed record keeping | Comprehensive data collection |
SS-31 Treatment Duration
| Research Objective | Minimum Duration | Optimal Period | Extended Studies |
|---|---|---|---|
| Safety Assessment | 2 weeks | 4 weeks | 12+ weeks |
| Efficacy Evaluation | 4 weeks | 8-12 weeks | 16+ weeks |
| Mechanism Studies | 2 weeks | 6-8 weeks | 12+ weeks |
| Clinical Translation | 8 weeks | 12-16 weeks | 24+ weeks |
SS-31 Storage Instructions
Optimized storage protocols maintain compound integrity across different research environments and study durations.
| Storage Condition | Temperature | Duration | Special Requirements |
|---|---|---|---|
| Lyophilized Form | -20??C | 2-3 years | Desiccated, light protection |
| Reconstituted | 2-8??C | 14 days | Sterile conditions maintained |
| Working Solutions | 2-8??C | 24-48 hours | Single-use preferred |
Why Choose SS-31 for Comparative Research?
SS-31’s versatility and well-established safety profile make it ideal for comparative research across multiple therapeutic areas. Its consistent formulation and predictable effects enable reliable study design and meaningful cross-study comparisons.
Summary
SS-31 provides researchers with a comprehensive mitochondrial support system suitable for diverse research applications. Its established safety profile, flexible dosing protocols, and consistent results make it valuable for comparative studies and therapeutic development across multiple health conditions.
SS-31 FAQ
You must be logged in to post a review.





Reviews
There are no reviews yet.